相关实验视频

Updated: Jun 12, 2025

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

使用Ga-FAPI PET/CT预测化学治疗的非霍奇金淋巴瘤的代谢反应:一个试点研究

Linwei Li^1,2,3, Hongyin Ding^1,2,3, Lingzhi Chen⁴

¹Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, China.

Cancer imaging : the official publication of the International Cancer Imaging Society

|June 8, 2025

概括

68 (Ga) 纤维细胞激活蛋白抑制剂 (FAPI) 定子发射断层扫描-计算机断层扫描 (PET/CT) 可以预测非霍奇金淋巴瘤 (NHL) 患者的治疗反应. 较低的Ga-FAPI吸收表明对化疗的反应不佳.

科学领域:

核医学是一种核医学.
在瘤学瘤学.
放射化学放射化学是指辐射化学.

背景情况:

非霍奇金淋巴瘤 (NHL) 是一组异构的恶性瘤.
循环胺-多克索鲁比HCl-温克里斯[Oncovin]-普雷尼松 (CHOP) 类化学疗法是NHL的标准治疗方法.
预测治疗反应对于优化患者治疗结果至关重要.

研究的目的:

评估Ga-FAPI PET/CT对接受CHOP类化疗的NHL患者代谢反应的预测值.
识别成像生物标志物,以便早期预测治疗疗效.

主要方法:

一项单中心前性研究招募了接受CHOP类化疗的NHL患者.
在开始治疗之前进行了Ga-FAPI PET/CT.
使用F-FDG PET/CT评估代谢反应,并对SUVmax,MTV和TLF进行定量分析.
计算了目标与背景的比率 (TBR血液和TBR肌肉).
进行了统计分析,包括曼·惠特尼U测试,后勤回归和ROC分析,以将成像参数与治疗反应相关联.

主要成果:

这项研究包括18名NHL患者.
与非响应者相比,响应者显示了显著更高的平均SUVmax,TBRblood和TBRmuscle.
在预测反应方面,SUVmax,TBRblood和TBRmuscle显示了曲线下的显著区域 (AUC).
SUVmax被确定为治疗结果的显著预后因素.

结论:

在PET/CT上低的Ga-FAPI吸收表明NHL患者对CHOP类疗法的代谢反应不佳.
来自Ga-FAPI PET/CT的SUVmax可以作为查可能对治疗有反应的患者的宝贵工具.

更多相关视频

An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use

An Automated Radiosynthesis of [⁶⁸Ga]Ga-FAPI-46 for Routine Clinical Use

Published on: May 24, 2024

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

相关概念视频

Positron Emission Tomography

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...